Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients

Phase 1TerminatedNCT00581243

Wyeth is now a wholly owned subsidiary of Pfizer32 enrolled

Overview

Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Healthy

Interventions

SLV-313 SRDRUG

sustained relase tablets taken once daily for 14 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men, aged 18-50 years old * Women, aged 18-50 years old Exclusion Criteria: * Non-lactating women, aged 18-50 years old * Non-pregnant women, aged 18-50 years old

Outcomes

Primary Outcomes

Observe safety and tolerability

Time frame: 25 days

Secondary Outcomes

PK and PD profile

Time frame: 25 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.